Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2007
08/23/2007WO2007029096A3 Novel polymorphic forms of clopidogrel hydrochloride
08/23/2007WO2007029062A3 Novel pyridine derivatives
08/23/2007WO2007023310A3 Stimulation of neurogenesis with help of alk inhibitors
08/23/2007WO2007015866A3 Inhibitors of p38 kinase and methods of treating inflammatory disorders
08/23/2007WO2007014154A3 10-substituted tetracyclines and methods of use thereof
08/23/2007WO2007009726A3 Method for producing pharmaceutical compositions containing glimepiride
08/23/2007WO2007008529A3 Celullar cholesterol absorption modifiers
08/23/2007WO2007008502A3 Inhibitors of checkpoint kinases
08/23/2007WO2007007183A3 Compositions of antiviral compound
08/23/2007WO2007007182A3 Solid and liquid dosage forms of an antiepileptic agent
08/23/2007WO2007007161A3 Novel bio-active derivatives
08/23/2007WO2007004072A3 Formulations and methods for treating amyloidosis
08/23/2007WO2007002314A9 Polymorphic forms of tegaserod maleate
08/23/2007WO2006134457A8 2,5-bis-diamimne [1 , 4] benzoquinone-derivatives
08/23/2007WO2006132879A3 Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols
08/23/2007WO2006124012A3 Compounds for treating alzheimer's disease and for inhibiting beta-amyloid peptide production
08/23/2007WO2006120568A3 Pharmaceutical composition containing an anti parasitic agent and an active ingredient selected from carveol, thymol, eugenol, borneol, carvacrol, alpha-ionone, or beta-ionone
08/23/2007WO2006120567A3 Pharmaceutical composition comprising an anti-bacterial agent and an active ingredient selected from carveol, thymol, eugenol, borneol and carvacrol
08/23/2007WO2006120565A3 Pharmaceutical combination comprising an antifungal agent and an active substance selected from carveol, eugenol, thymol, borneol, carvacrol and alpha- and beta-ionones
08/23/2007WO2006118954A8 Inhibition of reactive oxygen species and protection of mammalian cells
08/23/2007WO2006110588A8 Methods for treating mild cognitive impairment
08/23/2007WO2006097337A3 11β-HYDROXYSTEROID DEHYDROGENASES
08/23/2007WO2006096222A3 Nucleic acid ligands specific to immunoglobulin e and their use as atopic disease therapeutics
08/23/2007WO2006091720A3 Compositions and methods for targeted delivery of immune response modifiers
08/23/2007WO2006089015A3 Methods of using death receptor agonists and egfr inhibitors
08/23/2007WO2006083945A3 Rnai-mediated inhibition of ocular targets
08/23/2007WO2006081388A3 Substituted pyridazinyl-and pyrimidinyl-quinolin-4-ylamine analogues
08/23/2007WO2006074426A8 Cxcr4 antagonists for the treatment of hiv infection
08/23/2007WO2006071844A8 Oxygen-impervious packaging and methods for storing thyroid hormone
08/23/2007WO2006069998A9 Glycopyrrolate in cosmetic preparations
08/23/2007WO2006028545A3 Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
08/23/2007WO2005107817A3 Medical device with coating for capturing genetically-altered cells and methods of using same
08/23/2007WO2005089738A3 Use and administration of bacterial efflux pump inhibitors
08/23/2007WO2005069938A3 Extracellular superoxide dismutase (ec-sod) gene delivery to prevent oxidative injury
08/23/2007WO2005035003A9 Compositions and methods for increasing drug efficiency
08/23/2007WO2000024869A3 Methods for modulating cell fusion
08/23/2007WO2000021486A3 Prevention of uv-induced functional vitamin a deficiency through use of topically applied retinoid
08/23/2007US20070197829 Process for the synthesis and crystalline form agomelatine
08/23/2007US20070197821 Process for the preparation of high purity perindopril
08/23/2007US20070197793 Imidazolic compounds and use thereof as alpha-2 adrenergic receptors
08/23/2007US20070197783 Compositions and methods of treating cell proliferation disorders
08/23/2007US20070197775 Cytotoxic agents comprising taxanes and their therapeutic use
08/23/2007US20070197666 Pharmaceutical combination for the treatment of benign prostatic hyperplasia or for the long-term prevention of acute urinary retention
08/23/2007US20070197665 Obtained by reacting cyclic oligomer of (R)-3-hydroxybutyrate with a 3-keto-alkan-1-ol in an organic solvent in the presence of a lipase; acute trauma, hemorrhagic shock, neurodegeneration, diabetes, and epilepsy, stroke, head trauma, myocardial infraction, congestive heart failure, pulmonary failure
08/23/2007US20070197664 Prevention and treatment of androgen-deprivation induced osteoporosis
08/23/2007US20070197663 Methods of treating memory and cognitive impairments in humans following stroke and traumatic brain injury
08/23/2007US20070197662 Amine compounds and inhibiting neurotransmitter reuptake
08/23/2007US20070197661 Phenylephrine liquid formulations
08/23/2007US20070197660 Compounds for modulating cell proliferation
08/23/2007US20070197659 Antagonist of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
08/23/2007US20070197658 Polyamines and their use as antibacterial and sensitizing agents
08/23/2007US20070197657 Method for treating non-inflammatory musculoskeletal pain
08/23/2007US20070197656 reducing pro-inflammatory response in diseased cell of respiratory tract by contacting cell with an agent that increases ceramide levels in cell thereby reducing pro-inflammatory response in cell, wherein agent is fenretinide and diseased cell is representative of disease state of cystic fibrosis
08/23/2007US20070197655 Galenic formulations of organic compounds
08/23/2007US20070197654 Combination of a cb1 receptor antagonist and of a product which activates dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of parkinson's disease
08/23/2007US20070197653 Amide or thioamide derivatives and their use in the treatment of pain
08/23/2007US20070197652 Solid pharmaceutical composition for the treatment of the benign prostatic hyperplasia its preparation procedure and its therapeutical method
08/23/2007US20070197651 Treatment of stereotypic, self-injurious and compulsive behaviors in man and animals using antagonists of NMDA receptors
08/23/2007US20070197650 Ethers of 3-hydroxyphenylacetic acid as selective gamma-hydroxybutyric acid receptor ligands
08/23/2007US20070197649 Use of deferiprone and methods to treat and/or prevent Friedreich Ataxia resulting from intracellular mishandling of iron
08/23/2007US20070197648 Pharmaceutical product containing tranilast
08/23/2007US20070197647 Inhibitor for the onset and progress of liver cancer to be used in hepatitis c virus-positive human liver cirrhosis patients
08/23/2007US20070197646 Substituted taraxastanes useful for treating viral infections
08/23/2007US20070197645 Treatment of adhd
08/23/2007US20070197644 Use of 13-HODE as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
08/23/2007US20070197643 Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating inflammatory bowel disease
08/23/2007US20070197642 Androgen modulators
08/23/2007US20070197641 Androgen modulators
08/23/2007US20070197640 Certain chemical entities, compositions, and methods
08/23/2007US20070197639 Using ichthyin allelic expression profile to screen/diagnose/prognose syndromic autosomal recessive congenital ichthyosis (ARCI)
08/23/2007US20070197638 Weight loss induced by reduction in neuropeptide level
08/23/2007US20070197637 Use of oligosaccharide for preventing blood clotting in extracorporeal blood circuits
08/23/2007US20070197636 Coumarin Derivative And Use Thereof
08/23/2007US20070197635 such as 11-(4-Dimethylamino-phenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,8,11,12,13,14,15,16,17-decahydro-6H-7-oxa-cyclopenta[a]phenanthren-3-one, used for the treatment of breast cancer and adenocarcinoma, and non-insulin dependent diabetes
08/23/2007US20070197634 Tetracyclic steroid derivatives useful as progesterone receptor modulators
08/23/2007US20070197633 Novel forms of pravastatin sodium
08/23/2007US20070197632 Aminocyclohexyl ether compounds and uses thereof
08/23/2007US20070197631 Processes for preparing darifenacin hydrobromide
08/23/2007US20070197630 Pure darifenacin hydrobromide substantially free of oxidized darifenacin and salts thereof and processes for the preparation thereof
08/23/2007US20070197629 Indole derivative and application thereof
08/23/2007US20070197628 Cannabinoid receptor modulators
08/23/2007US20070197627 Indoline compound and process for producting the same
08/23/2007US20070197626 Indoline derivatives
08/23/2007US20070197625 Azabicyclic compounds, a process for their preparation and pharmaceutical compositions containing them.
08/23/2007US20070197624 such as N-{5-[1-(4-chloro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetylamino]-propionamide, used for inhibiting beta-amyloid peptide release and/or biosynthesis, inhibiting gamma-secretase activity, prevention and treatment of Alzheimer's disease
08/23/2007US20070197623 increases the effect on Sodium-dependent glucose cotransporters (SGLT); for lowering blood glucose; treatment of type 1 and type 2 diabetes; N-(2-Carbamoylethyl)-4-[1-(2-cyano-ethyl)-5-hydroxy-3-isopropyl-1H-pyrazol-4-ylmethyl]benzamide
08/23/2007US20070197622 Methods for treating CNS disorders with 4-imidazole derivatives
08/23/2007US20070197621 Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives
08/23/2007US20070197620 Methods for treating CNS disorders with bicyclo-substituted 2-imidazoline and 2-imidazoles
08/23/2007US20070197619 Ion Channel Modulators
08/23/2007US20070197618 (R)-N-(Benzimidazol-2-yl)-1,2,3,4-tetrahydro-1-naphthylamine, used for the treatment, prevention or alleviation of diseases or disorders that is responsive to modulation of potassium channels
08/23/2007US20070197617 2-[(S)-2-((S)-2,5-dioxo-4-phenyl-imidazolidin-1-yl)-4-methyl-pentanoylamino]-thiazole-4-carboxylic acid methyl ester; mitogen activated protein/extracellular signal regulated kinase kinase inhibitor; anticarcinogenic agent, cognition activator, nervous and autoimmune system disorders
08/23/2007US20070197616 Novel imidazolopyrazole derivatives useful as selective androgen receptor modulators
08/23/2007US20070197615 Process for the preparation of the PPAR alpha agonist NS-220
08/23/2007US20070197614 Method for the production of diarylcycloalkyl derivatives
08/23/2007US20070197613 2-{-3,'2-(phenyl)-oxazol-4-ylmethoxyl-cyclohexyl methoxy}-propionic acid derivatives used as peroxisome proliferator-activated receptor (ppar) ligands for the treatment of hyperlipidemia and diabetes
08/23/2007US20070197612 To modulate and control lipid and/or carbohydrate metabolism; atherosclerosis; acetic acid derivatives with cyclohexylmethoxy substituents; 2-[(1R,3S)-3-(2-Biphenyl-4-yl-5-methyloxazol-4-ylmethoxymethyl)cyclohexylmethoxy]-2-methylpropionic acid
08/23/2007US20070197611 Fermentative preparation process for and crystal forms of cytostatics
08/23/2007US20070197610 Benzisoxazoles
08/23/2007US20070197609 Salts of inducible nitric oxide synthase dimerization inhibitors
1 ... 3612 3613 3614 3615 3616 3617 3618 3619 3620 3621 3622 3623 3624 3625 3626 3627 3628 3629 3630 3631 3632 ... 7860